Cardiff Oncology Inc Earnings

The next earnings date for Cardiff Oncology Inc is October 30, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Cardiff Oncology Inc Earnings

Report DateEstimated Earnings Per Share
10/30/2025$-0.20

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Cardiff Oncology Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
05/09/2025---$-0.20-7.53%
02/26/2025After Market$-0.2115.15%
10/31/2024Before Market$-0.257.41%
08/08/2024After Market$-0.26-4.00%
05/02/2024After Market$-0.2212.00%
02/29/2024After Market$-0.2125.00%
11/02/2023After Market$-0.2221.43%
08/09/2023After Market$-0.253.85%
05/04/2023After Market$-0.25-8.70%
03/02/2023After Market$-0.2013.04%
11/03/2022After Market$-0.2023.08%
08/04/2022After Market$-0.244.00%
05/05/2022After Market$-0.25-8.70%
02/24/2022After Market$-0.23-35.29%
11/04/2021After Market$-0.170.00%
08/05/2021After Market$-0.17-13.33%
05/06/2021After Market$-0.146.67%
02/25/2021After Market$-0.19-35.71%
11/05/2020After Market$-0.190.00%
08/11/2020After Market$-0.51-112.50%
05/07/2020After Market$-0.41---
02/27/2020After Market$-0.5110.53%
11/07/2019After Market$-0.7115.48%
08/08/2019After Market$-0.79-49.06%
05/07/2019After Market$-1.024.67%
03/06/2019After Market$-1.09-3.81%
11/07/2018After Market$-1.0845.45%
08/03/2018After Market$-2.64-33.33%
05/08/2018After Market$-6.4821.74%
02/26/2018After Market$-4.3252.00%
11/09/2017Before Market$-8.6414.29%
08/09/2017After Market$-10.086.67%
05/10/2017After Market$-19.44-12.50%
03/15/2017After Market$-1821.88%
11/09/2016After Market$-24.48-4.62%
08/04/2016After Market$-24.48-9.68%
05/10/2016After Market$-25.20-19.04%
03/10/2016After Market$-18-0.67%
11/09/2015After Market$-7.2063.23%
08/10/2015After Market$-29.52-68.49%
05/05/2015After Market$-23.76-36.08%
03/12/2015After Market$-181.96%
11/06/2014After Market$-20.16-14.29%
08/07/2014---$-4.3270.97%
05/12/2014---$-12.2412.82%
03/17/2014---$-3.6073.68%
11/14/2013---$-18-11.11%
08/14/2013---$-10.80-3.45%
05/14/2013---$-5.0426.32%
03/31/2013---$-7.20-17.65%
11/28/2012---$-3.35---
08/29/2012---$-20.47---

More About Cardiff Oncology Inc

Website
https://www.cardiffoncology.com
Country
USA
Full Time Employees
32

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

“Cardiff Oncology Inc Earnings” Can Refer to the Cardiff Oncology Inc Earnings Date

Some people say “Cardiff Oncology Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Cardiff Oncology Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Cardiff Oncology Inc Stock on the Earnings Date

If you own Cardiff Oncology Inc stock (CRDF) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Cardiff Oncology Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Cardiff Oncology Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Cardiff Oncology Inc Earnings

You can contact us any time if you would like to ask questions about Cardiff Oncology Inc earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.